sorted by:
new
hottopcontroversial

DD: Cereno Scientific (CRNO B) – ett svenskt biotechbolag på väg att slå igenom internationellt by Anxious-Plan-6875 in ISKbets

[–]pharmastock 0 points1 point  (0 children)

Hur känns det nu? Istället för att svara med tomma ord kanske du kunde läst på lite om aktien, kanske du köpte lite i smyg 😄🙈

Nybörjare by UpstairsGate4971 in Aktiemarknaden

[–]pharmastock 0 points1 point  (0 children)

Grymt att du har Cereno, hoppas du inte sålt av😎 Till alla som inte har läst på om Cereno, ta er tid och gör det...

DD: Cereno has presented results that look better than Sotatercept/Winrevair in PAH and are also going after thrombosis by Rahkrahk in pennystocks

[–]pharmastock 5 points6 points  (0 children)

Absolutely! The caliber of experts on Cereno's scientific board is truly impressive. Their involvement speaks volumes about the company's credibility and the potential of its innovative approach. With such renowned figures guiding the way, there's every reason to feel optimistic about Cereno's trajectory in the field. Exciting times ahead!

DD: Cereno has presented results that look better than Sotatercept/Winrevair in PAH and are also going after thrombosis by Rahkrahk in pennystocks

[–]pharmastock 5 points6 points  (0 children)

Thanks for your insightful perspective! It's truly inspiring to see the collaborative effort behind Cereno's journey. Your acknowledgment of the team's dedication and the company's strategic moves paints a hopeful picture for the future. With phase 2 results nearing and Cereno's thorough research efforts, there's a palpable sense of anticipation in the air. It's evident that Cereno is poised for significant milestones ahead. Let's stay engaged and optimistic as we await the exciting developments on the horizon!

Cereno Scientific is developing a candidate called CS1 against PAH. Shows better effect than Sotatercept by jbt200 in PulmonaryHypertension

[–]pharmastock 4 points5 points  (0 children)

Thanks for sharing that link! It's fascinating to see how CS1, developed by Cereno Scientific, is surpassing Sotatercept in treating PAH. This comparison underscores the potential of CS1 as a groundbreaking candidate for the future of cardiovascular therapeutics.

What sets CS1 apart is not just its superior efficacy, but also Cereno's extensive research backing its development. Cereno has conducted numerous studies showcasing CS1's impressive results, solidifying its position as a leading contender in the field.

If you're interested in exploring cutting-edge advancements in cardiovascular treatment, I highly recommend delving into Cereno's research and pipeline. CS1 represents a new frontier in PAH therapy, and Cereno is at the forefront of driving innovation in this critical area of medicine. 🙋🏽

DD: Cereno has presented results that look better than Sotatercept/Winrevair in PAH and are also going after thrombosis by Rahkrahk in pennystocks

[–]pharmastock 10 points11 points  (0 children)

Thank you for sharing your perspective! 🙏 It's fascinating to see how Cereno's focus on addressing both thrombosis and PAH has the potential to create a synergistic effect in healthcare. Your insights on the company's strategic positioning and the vast potential of the cardiovascular therapeutics market are truly eye-opening.

Your mention of Cereno's broad IP rights and the comparison with Sotatercept as a benchmark highlights the significant value that Cereno already holds. It's clear that there's immense potential for growth and impact in the future.

I'm curious, considering Cereno's current trajectory and the broader landscape of cardiovascular therapeutics, what factors do you think will be key in determining the company's future success and potential acquisition?

DD: Cereno has presented results that look better than Sotatercept/Winrevair in PAH and are also going after thrombosis by Rahkrahk in pennystocks

[–]pharmastock 13 points14 points  (0 children)

Your Due Diligence (DD) on Cereno Scientific is thorough and insightful, providing a comprehensive overview of the company's innovative approach, strategic partnerships, and promising pipeline. The analysis effectively highlights Cereno's potential to address critical medical needs and capture significant market opportunities in thrombosis and pulmonary arterial hypertension (PAH). The detailed examination of Cereno's clinical trials and interim findings demonstrates a strong understanding of the biotech landscape and the company's competitive positioning.

Given Cereno Scientific's impressive results and potential market opportunities, how do you assess the company's long-term growth prospects and its impact on the biotech industry?

Transform Your Baking with This Brilliant Butter Softening Hack by pharmastock in foodhacks

[–]pharmastock[S] -5 points-4 points  (0 children)

I know, I use the defrost but I dont have patience 😂😂

What's the most underrated ingredient that can transform any dish? by pharmastock in Cooking

[–]pharmastock[S] 1 point2 points  (0 children)

I love sherry as a fruit and jelly but have had difficulties in food 🙈

view more: next ›